Impact of tumour growth rate during preceding treatment on tumour response to regorafenib or trifluridine/tipiracil in refractory metastatic colorectal cancer

BACKGROUND: Although regorafenib (REG) and trifluridine/tipiracil (FTD/TPI) have been recognised as standard treatments in metastatic colorectal cancer (mCRC), the best option remains unclear. Pretreatment tumour growth rate (TGR) is associated with radiotherapeutic efficacy in laryngeal cancer. How...

Descripción completa

Detalles Bibliográficos
Autores principales: Masuishi, Toshiki, Taniguchi, Hiroya, Kawakami, Takeshi, Kawamoto, Yasuyuki, Kadowaki, Shigenori, Onozawa, Yusuke, Muranaka, Tetsuhito, Tajika, Masahiro, Yasui, Hirofumi, Nakatsumi, Hiroshi, Yuki, Satoshi, Muro, Kei, Omae, Katsuhiro, Komatsu, Yoshito, Yamazaki, Kentaro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7001098/
https://www.ncbi.nlm.nih.gov/pubmed/32392174
http://dx.doi.org/10.1136/esmoopen-2019-000584

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7001098/
https://www.ncbi.nlm.nih.gov/pubmed/32392174
http://dx.doi.org/10.1136/esmoopen-2019-000584

Ejemplares similares